EAE Model of Multiple Sclerosis
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis. This model is produced by administering a myelin basic protein peptide (MBP) fragment that induces an autoimmune response directed to the myelin sheath surrounding motor neurons.
Demyelination of neurons within the CNS leads to impaired locomotor function and mirrors symptoms of the human disease. As with multiple sclerosis in humans, the condition in rodents appears in relapsing-remitting cycles and are characterized by loss of nerve conduction and chronic progression of disability.
This study described below assesses the progression of locomotor dysfunction in mice subjected to EAE to and validated with the immune modulator FTY-720 (fingolimod; Gilenya®) thereby validating this as multiple sclerosis model (MS model).
|0||No clinical signs; normal activity|
|1||Limp tail or hind limb weakness, but not both|
|2||Limp tail and hind limb weakness|
|3||Partial hind limb paralysis|
|4||Complete hind limb paralysis|
|5||Moribund state; death by EAE|
The EAE Multiple Sclerosis Model can be performed in mice or rats. Typical study duration is about 21 days.